Cargando…
Preclinical development of BCG.HIVA(2auxo.int), harboring an integrative expression vector, for a HIV-TB Pediatric vaccine. Enhancement of stability and specific HIV-1 T-cell immunity
One of the critical issues that should be addressed in the development of a BCG-based HIV vaccine is genetic plasmid stability. Therefore, to address this issue we have considered using integrative vectors and the auxotrophic mutant of BCG complemented with a plasmid carrying a wild-type complementi...
Autores principales: | Mahant, Aakash, Saubi, Narcís, Eto, Yoshiki, Guitart, Núria, Gatell, Josep Ma, Hanke, Tomáš, Joseph, Joan |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Taylor & Francis
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5557246/ https://www.ncbi.nlm.nih.gov/pubmed/28426273 http://dx.doi.org/10.1080/21645515.2017.1316911 |
Ejemplares similares
-
Newborn Mice Vaccination with BCG.HIVA(222) + MVA.HIVA Enhances HIV-1-Specific Immune Responses: Influence of Age and Immunization Routes
por: Saubi, Narcís, et al.
Publicado: (2011) -
Pre-Clinical Development of BCG.HIVA(CAT), an Antibiotic-Free Selection Strain, for HIV-TB Pediatric Vaccine Vectored by Lysine Auxotroph of BCG
por: Saubi, Narcís, et al.
Publicado: (2012) -
Pre-clinical development of BCG.HIVA(CAT) strain, an antibiotic-free selection strain for HIV-TB pediatric vaccine
por: Saubi, N, et al.
Publicado: (2012) -
P17-17. Newborn mice vaccination with rBCG:HIVA + MVA:HIVA enhances HIV-1-specific immune responses. Influence of age and immunization routes
por: Saubi, N, et al.
Publicado: (2009) -
Engineering new mycobacterial vaccine design for HIV–TB pediatric vaccine vectored by lysine auxotroph of BCG
por: Saubi, Narcís, et al.
Publicado: (2014)